Belgium Janssen has the lofty aim of reaching USD 60bn dollars in sales by 2025, an 8bn increase on the 2021 figure, despite some high-profile losses of exclusivity and the spin-off of its consumer healthcare branch. This massive growth plan involves both existing products as well as new CAR-T and autoimmune…
Global Global biopharma is increasingly moving towards biologic medicines, which promise a greater impact on patient’s lives than the small-molecule drugs that preceded them, but which come with significant added costs and complexity. Against this backdrop, biologic drug developers are leaning evermore on experienced contract development and manufacturing organizations (CDMOs), of…
Belgium Maria Fernanda Prado highlights some of the lessons drawn from her extensive experience in emerging markets which remain applicable in her current role as Janssen’s managing director for the Benelux region. Belgium, the home country of Dr Paul Janssen, continues to be a significant part of the company’s global operations,…
Takeda Japanese-headquartered Takeda has been undergoing a transformation in recent years, becoming the global leader in rare diseases with the acquisition of Shire in 2018 and divesting ‘non-core’ assets in OTC and consumer goods. Here, four country and regional managers that PharmaBoardroom has spoken to in the past 12 months discuss…
UAE Amgen’s Mohammed Nasser casts his eye on some of the key trends affecting healthcare and the life sciences in the Middle East and Africa, including a significant maturity in uptake of digital and telehealth tools, better synchronisation of electronic medical records, and how artificial intelligence can be used to better…
Denmark Danish allergy specialist ALK will have a new CEO in 2024, with current incumbent Carsten Hellmann set to step down after a seven-year spell in the hot seat. Hellmann, 59, will be replaced by the comparatively youthful 45-year-old Peter Halling at the end of the year, which ALK Board Chairman…
Greece One of Greece’s leading domestic pharmaceutical companies, RAFARM has had a stellar recent history, including a momentous entry into the US market. Now looking to establish itself as one of Europe’s major players in ophthalmics and complex injectables, VP Aris Mitsopoulos highlights the key learnings from this US experience and…
USA During the ongoing BIO International Convention in Boston between June 5th and 8th, the US lobbying group has announced a new board chair in Ted Love as well as a new executive committee. Love is a longstanding BIO board director and the former President & CEO of Global Blood…
Greece Greece’s deep and painful sovereign debt crisis lasted almost a decade and saw up to 500,000 Greeks leave the country in search of opportunities elsewhere as the country’s economy shrunk by a quarter and unemployment shot up to 28 percent. 26 percent of those emigrating held a degree, and 69…
Belgium Luc Van Gorp is president of the Christian Mutuality, Belgium’s largest health insurance fund. In a wide-ranging recent conversation with PharmaBoardroom, Van Gorp expanded on some of the key themes in his 2021 book ‘Human Scale: A Plea for Imperfection’ (‘Mensenmaat: Een Pleidooi Voor Imperfectie’ in Dutch), including why innovation…
China John Oyler, co-founded the Beijing-based biotech BeiGene in 2010 with the idea of building a global biopharmaceutical company in China and running clinical trials of an international standard there. With his entrepreneurial background and knowledge of China and its life sciences ecosystem, Oyler has led the company through its consolidation…
LatAm Having spent 25 years in the rare disease arena, Maria Gabriella Pittis now finds herself at the forefront of a different field, spearheading the launch of Takeda’s dengue vaccine across Latin America. Pittis, an Argentinian native, is a previous employee of the Argentinian National Scientific and Technical Research Council…
See our Cookie Privacy Policy Here